Q3 2025 · 13F-HR
RA CAPITAL MANAGEMENT, L.P.holdings as filed
Filed 2025-11-14 · accession 0001104659-25-112469
$8.12B
Reported value
67
Positions
2025-09-30
Period end
The Brief · RA CAPITAL MANAGEMENT, L.P. · Q3 2025
AI · grounded in 13F
RA CAPITAL MANAGEMENT, L.P. established a new position in ASCENDIS PHARMA A/S - ADR ASNDUSD valued at $2.04B. The fund also opened new stakes in RHYTHM PHARMACEUTICALS INC RYTM for $573.8M and VAXCYTE INC PCVX for $431M. Additional new positions include AVIDITY BIOSCIENCES INC RNAGBP and CIDARA THERAPEUTICS INC CDTX. The fund manages a total AUM of $8.12B across 67 positions.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 04351P101 | ASNDUSD | ASCENDIS PHARMA A/S - ADR | $2.04B | 25.2% | 10,281,496 | Common | SOLE |
| 76243J105 | RYTM | RHYTHM PHARMACEUTICALS INC | $573.8M | 7.07% | 5,681,359 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $431.0M | 5.31% | 11,965,991 | Common | SOLE |
| 05370A108 | RNAGBP | AVIDITY BIOSCIENCES INC | $376.5M | 4.64% | 8,641,031 | Common | SOLE |
| 171757206 | CDTX | CIDARA THERAPEUTICS INC | $322.3M | 3.97% | 3,365,523 | Common | SOLE |
| 829401108 | SION | SIONNA THERAPEUTICS INC | $307.2M | 3.79% | 10,445,322 | Common | SOLE |
| 282559103 | ETNBGBP | 89BIO INC | $292.4M | 3.60% | 19,889,683 | Common | SOLE |
| N62509109 | NAMS | NEWAMSTERDAM PHARMA CO NV | $288.4M | 3.55% | 10,138,938 | Common | SOLE |
| 603170101 | MLYS | MINERALYS THERAPEUTICS INC | $277.7M | 3.42% | 7,323,750 | Common | SOLE |
| 47103J105 | JANX | JANUX THERAPEUTICS INC | $273.5M | 3.37% | 11,189,693 | Common | SOLE |
| 03940C100 | ACLXGBX | ARCELLX INC | $249.3M | 3.07% | 3,036,527 | Common | SOLE |
| 52635N103 | LENZ | LENZ THERAPEUTICS INC | $194.6M | 2.40% | 4,178,823 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $170.7M | 2.10% | 12,198,625 | Common | SOLE |
| 28036F105 | EWTX | EDGEWISE THERAPEUTICS INC | $169.1M | 2.08% | 10,428,437 | Common | SOLE |
| Y95308105 | WVE | WAVE LIFE SCIENCES LTD | $133.2M | 1.64% | 18,202,009 | Common | SOLE |
| 81734D104 | SEPN | SEPTERNA INC | $131.6M | 1.62% | 6,995,858 | Common | SOLE |
| 252828108 | DNTH | DIANTHUS THERAPEUTICS INC | $112.8M | 1.39% | 2,866,733 | Common | SOLE |
| 055477103 | BCAX | BICARA THERAPEUTICS INC | $109.8M | 1.35% | 6,955,993 | Common | SOLE |
| G3855L106 | GHRS | GH RESEARCH PLC | $109.8M | 1.35% | 7,676,697 | Common | SOLE |
| 82835W108 | SPRY | ARS PHARMACEUTICALS INC | $109.2M | 1.34% | 10,860,977 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC-A | $107.8M | 1.33% | 1,246,456 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE INC | $104.2M | 1.28% | 1,577,106 | Common | SOLE |
| 929033207 | VOR | VOR BIOPHARMA INC | $96.6M | 1.19% | 1,982,301 | Common | SOLE |
| 359616109 | FULC | FULCRUM THERAPEUTICS INC | $94.1M | 1.16% | 10,229,099 | Common | SOLE |
| 713317105 | PEPG | PEPGEN INC | $92.7M | 1.14% | 20,064,545 | Common | SOLE |
| 374163103 | GERN | GERON CORP | $82.7M | 1.02% | 60,379,366 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $77.0M | 0.95% | 23,555,648 | Common | SOLE |
| 07782B104 | BLTE | BELITE BIO INC - ADR | $64.8M | 0.80% | 875,000 | Common | SOLE |
| 28658R106 | CLYM | CLIMB BIO INC | $63.2M | 0.78% | 31,419,267 | Common | SOLE |
| 80706P103 | SRRK | SCHOLAR ROCK HOLDING CORP | $43.5M | 0.54% | 1,166,788 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $42.5M | 0.52% | 1,517,418 | Common | SOLE |
| 61023L207 | MNPR | MONOPAR THERAPEUTICS INC | $41.8M | 0.51% | 511,207 | Common | SOLE |
| 35104E100 | FDMT | 4D MOLECULAR THERAPEUTICS IN | $39.7M | 0.49% | 4,563,211 | Common | SOLE |
| 83422E204 | SLDB | SOLID BIOSCIENCES INC | $35.9M | 0.44% | 5,811,423 | Common | SOLE |
| 59267L107 | — | METSERA INC | $35.4M | 0.44% | 675,525 | Common | SOLE |
| 04317A107 | ARTV | ARTIVA BIOTHERAPEUTICS INC | $28.3M | 0.35% | 9,853,302 | Common | SOLE |
| 50180M108 | LBRX | LB PHARMACEUTICALS INC | $28.1M | 0.35% | 1,776,958 | Common | SOLE |
| 89422G107 | TVTX | TRAVERE THERAPEUTICS INC | $27.5M | 0.34% | 1,150,000 | Common | SOLE |
| 045396207 | ASMB | ASSEMBLY BIOSCIENCES INC | $26.1M | 0.32% | 1,020,410 | Common | SOLE |
| 00509G209 | ABOS | ACUMEN PHARMACEUTICALS INC | $25.5M | 0.31% | 14,932,063 | Common | SOLE |
| 21217B100 | CTNM | CONTINEUM THERAPEUTICS INC-A | $24.9M | 0.31% | 2,122,000 | Common | SOLE |
| 65487U108 | NKTX | NKARTA INC | $22.4M | 0.28% | 10,805,129 | Common | SOLE |
| 517125100 | LRMR | LARIMAR THERAPEUTICS INC | $19.5M | 0.24% | 6,045,351 | Common | SOLE |
| 00534A102 | IVVD | INVIVYD INC | $18.8M | 0.23% | 17,119,096 | Common | SOLE |
| 87583X109 | TNGX | TANGO THERAPEUTICS INC | $16.8M | 0.21% | 2,000,000 | Common | SOLE |
| 74168J101 | PRME | PRIME MEDICINE INC | $16.6M | 0.20% | 3,000,000 | Common | SOLE |
| 03969F109 | RCUS | ARCUS BIOSCIENCES INC | $15.5M | 0.19% | 1,136,364 | Common | SOLE |
| 004890109 | ACRV | ACRIVON THERAPEUTICS INC | $15.1M | 0.19% | 8,340,508 | Common | SOLE |
| 95075A107 | HOWL | WEREWOLF THERAPEUTICS INC | $13.2M | 0.16% | 6,681,307 | Common | SOLE |
| N90064101 | QURE | UNIQURE NV | $11.7M | 0.14% | 200,000 | Common | SOLE |
| 28617K101 | ELDN | ELEDON PHARMACEUTICALS INC | $9.2M | 0.11% | 3,566,338 | Common | SOLE |
| 008064206 | JBIO | JADE BIOSCIENCES INC | $9.2M | 0.11% | 1,062,326 | Common | SOLE |
| 78397T202 | SABS | SAB BIOTHERAPEUTICS INC | $8.8M | 0.11% | 4,401,500 | Common | SOLE |
| 457730109 | INSP | INSPIRE MEDICAL SYSTEMS INC | $8.5M | 0.11% | 114,901 | Common | SOLE |
| 23284F105 | CTMX | CYTOMX THERAPEUTICS INC | $8.5M | 0.10% | 2,661,331 | Common | SOLE |
| 05338F306 | AVTX | AVALO THERAPEUTICS INC | $8.4M | 0.10% | 662,968 | Common | SOLE |
| G70077105 | PCSC | PERCEPTIVE CAPITAL SOLUTIONS | $8.0M | 0.10% | 750,000 | Common | SOLE |
| 86889P208 | SRZN | SURROZEN INC | $7.8M | 0.10% | 602,626 | Common | SOLE |
| 81663L200 | WGS | GENEDX HOLDINGS CORP | $6.3M | 0.08% | 58,044 | Common | SOLE |
| 007002108 | TORCEUR | ADICET BIO INC | $6.1M | 0.08% | 7,541,000 | Common | SOLE |
| N62509117 | NAMSW | NEWAMSTERDAM PHARMA CO NV-27 | $5.7M | 0.07% | 333,333 | Common | SOLE |
| 30050B101 | EVH | EVOLENT HEALTH INC - A | $4.9M | 0.06% | 579,052 | Common | SOLE |
| 377322102 | GKOS | GLAUKOS CORP | $4.4M | 0.05% | 54,180 | Common | SOLE |
| 25056L103 | DSGN | DESIGN THERAPEUTICS INC | $3.6M | 0.04% | 475,699 | Common | SOLE |
| 30063P105 | EXK | EXACT SCIENCES CORP | $3.0M | 0.04% | 54,939 | Common | SOLE |
| N44821101 | IFRX | INFLARX NV | $2.6M | 0.03% | 1,973,233 | Common | SOLE |
| 74340E103 | PGNY | PROGYNY INC | $2.1M | 0.03% | 96,628 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.